

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
26 November 2020 (26.11.2020)



(10) International Publication Number
WO 2020/237227 A1

(51) International Patent Classification:

A61K 48/00 (2006.01) A61K 31/7105 (2006.01)
A61K 31/7088 (2006.01) C07K 14/725 (2006.01)
C12N 15/115 (2010.01) C12N 15/85 (2006.01)
C12N 15/64 (2006.01) C12N 15/11 (2006.01)

(21) International Application Number:

PCT/US2020/034418

(22) International Filing Date:

22 May 2020 (22.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/851,548	22 May 2019 (22.05.2019)	US
62/857,121	04 June 2019 (04.06.2019)	US
PCT/US2019/035531	05 June 2019 (05.06.2019)	US
62/943,796	04 December 2019 (04.12.2019)	US
62/943,779	04 December 2019 (04.12.2019)	US
62/972,194	10 February 2020 (10.02.2020)	US

(71) Applicants: **MASSACHUSETTS INSTITUTE OF TECHNOLOGY** [US/US]; 77 Massachusetts Avenue, Cambridge, MA 02139 (US). **ORNA THERAPEUTICS, INC.** [US/US]; 450 Kendal Street, Cambridge, MA 02142 (US).

(72) Inventors; and

(71) Applicants (for US only): **WESSELHOEFT, Alexander** [US/US]; c/o Orna Therapeutics, Inc., 450 Kendal Street, Cambridge, MA 02142 (US). **ANDERSON, Daniel, G.** [US/US]; c/o Orna Therapeutics, Inc., 450 Kendal Street, Cambridge, MA 02142 (US). **FUSE, Shinichiro** [US/US]; c/o Orna Therapeutics, Inc., 450 Kendal Street, Cambridge, MA 02142 (US). **GOODMAN, Brian** [US/US]; c/o Orna Therapeutics, Inc., 450 Kendal Street, Cambridge, MA 02142 (US). **HORHOTA, Allen** [US/US]; c/o Orna Therapeutics, Inc., 450 Kendal Street, Cambridge, MA 02142 (US). **SQUILLONI, Raffaella** [US/US]; c/o Orna Therapeutics, Inc., 450 Kendal Street, Cambridge, MA 02142 (US).

(74) Agent: **SHUSTER, Michael, J.** et al.; c/o Patent Administrator, Goodwin Procter LLP, 100 Northern Avenue, Boston, MA 02210 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: CIRCULAR RNA COMPOSITIONS AND METHODS

(57) Abstract: Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.



WO 2020/237227 A1